Biomarker Discovery Solutions for Lymphoma & Multiple Myeloma Comprehensive Characterization of Genetic Events With Combinatorial DNA and RNA Profiling Travis Yates, PhD Field Application Scientist Lymphoma and multiple myeloma account for more than 65 percent of newly diagnosed hematological cancer cases. The genetic landscape of these [...]
Biomarker Discovery Solutions for Lymphoma and Multiple Myeloma Comprehensive Characterization of Genetic Events With Combinatorial DNA and RNA Profiling The ImmunoID NeXT Platform® offers customers an optimized assay by combining highly-sensitive, exome-scale DNA and RNA sequencing, along with fully integrated advanced analytics to provide a multidimensional view of the [...]
Introduction to Liquid Biopsies Maik M. Pruess, PhD Sr. Field Application Scientist The liquid biopsy is a relatively new concept that has gained traction over the last several years. Circulating tumor DNA (ctDNA) fragments are released by tumor cells into the blood, and contain [...]
Current Challenges in Liquid Biopsies Maik M. Pruess, PhD Sr. Field Application Scientist The liquid biopsy has the potential to change cancer research and clinical care through a variety of applications, from early detection and monitoring, to detection of drug resistance and minimal residual [...]
NeXT Liquid Biopsy™ It’s Time to Think About More. High-Performance Whole Exome Sequencing from Plasma. Complementing Tumor Tissue Profiling with Plasma-based Global Resolution NeXT Liquid Biopsy™, a high-performance, exome-wide liquid biopsy assay, is designed to complement Personalis’ flagship tissue-based immunogenomics platform, ImmunoID NeXT™, to further enhance the development of [...]
Provider FAQs for NeXT Dx™ Test This document covers Provider FAQs and cancer genes of clinical importance covered by the Personalis NeXT Dx™ Test.
2020 EACR Liquid Biopsies Sponsored Symposia NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics Erin Newburn, PhD Associate Director, Field Applications Scientist Dan Norton, MBA Sr. Product Manager NeXT Liquid Biopsy™, a first-of-its-kind, high-performance exome-wide [...]
2020 SITC: Orthogonally and functionally validated algorithm for detecting HLA loss of heterozygosity T cells can inhibit tumor growth and progression by recognizing major histocompatibility complex class I (MHC-I) -bound peptides derived from antigens that are mutated, inappropriately expressed, or overexpressed in the tumor cells (vs. healthy cells). There are many mechanisms by which [...]
2020 SITC: B-cell receptor heavy chain repertoire profiling using an augmented transcriptome Comprehensively profiling the tumor and tumor microenvironment (TME) can help provide a more complete view of the complex interactions between the tumor and immune system, potentially furthering our understanding of tumor progression and response to treatment. We have developed an augmented, immuno-oncology-optimized exome/transcriptome [...]
2020 SITC: Profiling tumor circulating cell-free DNA with an enhanced whole-exome to enable sensitive assessment of somatic mutations The analysis of tumors using circulating cell-free DNA (cfDNA) is beginning to transform cancer diagnosis, prognosis, response to therapy and to enable disease progression monitoring. Most cfDNA assays are centered around the identification of therapeutically actionable [...]